These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2064730)

  • 1. Circadian secretion pattern of melatonin in Parkinson's disease.
    Fertl E; Auff E; Doppelbauer A; Waldhauser F
    J Neural Transm Park Dis Dement Sect; 1991; 3(1):41-7. PubMed ID: 2064730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa.
    Fertl E; Auff E; Doppelbauer A; Waldhauser F
    J Neural Transm Park Dis Dement Sect; 1993; 5(3):227-34. PubMed ID: 8369102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease.
    Bordet R; Devos D; Brique S; Touitou Y; Guieu JD; Libersa C; Destée A
    Clin Neuropharmacol; 2003; 26(2):65-72. PubMed ID: 12671525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The accelerated aging hypothesis of Parkinson's disease is not supported by the pattern of circadian melatonin secretion.
    Sandyk R
    Int J Neurosci; 1997 Aug; 90(3-4):271-5. PubMed ID: 9352432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined use of benserazide and carbidopa in Parkinson's disease.
    Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
    Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin secretion in patients with Parkinson's disease receiving different-dose levodopa therapy.
    Kataoka H; Saeki K; Kurumatani N; Sugie K; Obayashi K
    Sleep Med; 2020 Nov; 75():309-314. PubMed ID: 32950012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
    Bender DA; Earl CJ; Lees AJ
    Clin Sci (Lond); 1979 Jan; 56(1):89-93. PubMed ID: 477187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential pattern of the circadian rhythm of serum melatonin in young and elderly healthy subjects.
    Ohashi Y; Okamoto N; Uchida K; Iyo M; Mori N; Morita Y
    Biol Signals; 1997; 6(4-6):301-6. PubMed ID: 9500669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 17. Blunted Melatonin Circadian Rhythm in Parkinson's Disease: Express Bewilderment.
    Turkistani A; Al-Kuraishy HM; Al-Gareeb AI; Negm WA; Bahaa MM; Metawee ME; El-Saber Batiha G
    Neurotox Res; 2024 Aug; 42(5):38. PubMed ID: 39177895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease.
    Bolitho SJ; Naismith SL; Rajaratnam SM; Grunstein RR; Hodges JR; Terpening Z; Rogers N; Lewis SJ
    Sleep Med; 2014 Mar; 15(3):342-7. PubMed ID: 24529544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diurnal worsening in Parkinson patients treated with levodopa].
    Piccini P; Del Dotto P; Pardini C; D'Antonio P; Rossi G; Bonuccelli U
    Riv Neurol; 1991; 61(6):219-24. PubMed ID: 1813974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.